A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma

Schoenfeld, D., Djureinovic, D., Zhang, L., Mann, J., Huck, J., Jilaveanu, L., … Kluger, H. (2023). A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma. The Oncologist, 28(Supplement_1), S7–S7. https://doi.org/10.1093/oncolo/oyad216.010